Organigram Global Inc.

NASDAQ:OGI

Drug Manufacturers - Specialty & Generic

Healthcare
$0.68 -1.74%

-$0.02 today

Market cap
$95.40M
Beta
1.84
P/E (TTM)
-7.2
EPS (TTM)
-$0.19
52W Low $0.97High $2.24

Volume 0.62M

Average 0.67M

OGI Operating Cash Flow

Cash generated by the company's core business operations during the period.

Organigram Global Inc.NASDAQ: OGI

Operating Cash Flow · Q2 FY2026 · quarter ended Mar 2026

Operating cash flow declines year over year

Q2 FY2026 operating cash flow of CA$6.32M (cash outflow) fell 61.9% year over year, behind the -46.2% change in trailing-twelve-month operating cash flow. Sequentially, it fell 59.9% from the prior quarter.

Context

  • Operating cash flow amounted to 2.3% of revenue in FY2025, down 0.1 pp from a year earlier.
  • Operating cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -61.9% toward the trailing-twelve-month pace of -46.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$6.32M-59.9% QoQ
Last fiscal yearSep 2025
-CA$4.3M-211.1% YoY
LTMMar 2026
-CA$8.39M-46.2% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-61.9%——
1 year-211.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

CAD · from the cash flow

Latest · FY2025
(4.3M) CAD
Year-over-year change
-211.1%

Operating Cash Flow vs competitors

How OGI compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -46.2% is the 8th highest of 9, against a peer median of +4.4%.
  • Operating cash flow amounts to 3.1% of revenue for OGI, versus a peer median of 16.6%.
OGI Competitors
Operating Cash Flow for OGI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€100.98M EUR+17.5%+31.0%2252.6%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$72.97M USD+136.4%+32.7%4110.9%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$54.52M USD+0.8%+18.7%166.6%
INFUInfuSystem Holdings, Inc.LTM Mar 2026$23.6M USD+7.9%+11.7%16.6%
HSDTSolana CompanyLTM Mar 2026$17.81M USD+53.8%+4.9%185.7%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$17.38M USD—-79.1%12.9%
ACBAurora Cannabis Inc.LTM Mar 2026CA$13.51M CAD-184.4%-51.1%4.3%
ELMDElectromed, Inc.LTM Mar 2026$10.53M USD-12.4%—14.7%
OGIOrganigram Global Inc.LTM Mar 2026CA$8.39M CAD-46.2%—3.1%
DERMJourney Medical CorporationLTM Mar 2026$6.78M USD-2.4%-2.8%10.5%
Peer median (excluding OGI) —+4.4%+8.3%16.6%

Competitors are the stored peer set for OGI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(130.7M)(14.28M)(229.48M)(45.44M)(24.76M)
Depreciation & Amortization31.03M24.91M24.08M12.08M17.98M
Deferred Income Tax42.21M(88K)(2.66M)0(13.77M)
Stock-Based Compensation3.9M5.13M5.29M7.18M4.22M
Change in Working Capital24.2M(22.88M)12.51M14.96M(2.12M)
Accounts Receivables(6.01M)(24.02M)12.51M(12.06M)(15.29M)
Inventory28.68M(12.22M)000
Accounts Payables2.06M12.15M000
Other Working Capital(542K)1.21M(4.06M)27.02M13.16M
Other Non-Cash Items776K(29M)151.8M15.09M14.16M
Operating Cash Flow(28.59M)(36.21M)(35.8M)3.87M(4.3M)
Capital Expenditures(12.33M)(48.78M)(26.9M)(5.34M)(12.22M)
Acquisitions (Net)(2.54M)(11.06M)00(65.62M)
Purchases of Investments(120.02M)(15M)(7.36M)(29.24M)(1.01M)
Sales of Investments50.85M114.59M36.37M3.52M2.5M
Other Investing Activities(31.08M)4.29M31.46M(8.32M)21.8M
Investing Cash Flow(115.11M)44.03M4.56M(38.77M)(59.35M)
Debt Repayment(116.4M)(1.01M)(64.04K)(786K)(43.08K)
Common Stock Issued284.88M6.34M20K108.56M29.57M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.99M6.34M(754.15K)6K(1.29M)
Financing Cash Flow174.46M5.33M(754.15K)107.78M28.24M
Effect of Forex Changes0000(2.57M)
Net Change in Cash30.77M13.15M(68.52M)72.88M(37.98M)
Free Cash Flow(40.92M)(84.99M)(62.7M)(1.47M)(16.52M)

Organigram Global Inc.

NASDAQ:OGI

Intrinsic Alpha fair value

Locked

Current Price

$0.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.